Natural saponin-based synthetic immunoadjuvants
US-2015050319-A1 · Feb 19, 2015 · US
US12497429B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12497429-B2 |
| Application number | US-201916981939-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 20, 2019 |
| Priority date | Mar 20, 2018 |
| Publication date | Dec 16, 2025 |
| Grant date | Dec 16, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are variants of saponins that are found in Quillaja saponaria (QS) Molina tree bark that are chemically modified to distinguish them from naturally occurring parent saponins. The modified saponins have increased adjunctive activity compared to the unmodified parent saponins. Defined structures allow for comparisons of the modifying groups with respect to their respective adjunct activity and permit characterized vaccine formulations that have one or more defined saponins.
Opening claim text (preview).
What is claimed: 1 . A modified saponin having the formula: wherein: f3 and f4 are each independently OH, acetyl, or a cyclic ketal ring or cyclic carbonate ester formed by the C3 and C4 of the fucosyl unit, f3, and f4; f5 is a methyl group, a carboxyl group, R 4 -NR 5 -C(O)—, or an alkoxy group having the structure R 4 —O—, wherein R 4 and R 5 are each independently a linear chain having the structure R 6 (CH 2 ) 0-20 —, and wherein R 6 is H, OH, COOH, COOMe, COOEt, COOiPr, COOtBu, or COOBn; r3 is H, a monosaccharide, a disaccharide, or a trisaccharide; x3 is H, a monosaccharide, or a disaccharide; ga5 is a carboxyl group, R 4 —NR 5 —C(O)—, or an alkoxy group having the structure R 4 —O—, R 4 is a linear chain having the structure R 7 (CH 2 ) 0-20 —, and wherein R 7 is OH, COOH, COOMe, COOEt, COOiPr, COOtBu, COOBn, a monophosphoryl lipid A (MPL), or a dipalmitoyl-S-glyceryl cysteine (PamCys) unit, wherein R 5 is a linear chain having the structure R 8 (CH 2 ) 0-20 —, and wherein R 8 is H, OH, COOH, COOMe, COOEt, COOiPr, COOtBu, COOBn, a saccharide unit, a monophosphoryl lipid A (MPL), or a dipalmitoyl-S-glyceryl cysteine (PamCys) unit; and when f3 and f4 are both OH and f5 is a methyl group, ga5 is not a carboxyl group or COOH(CH 2 ) 0-20 —NH—C(O)—. 2 . A modified saponin having the formula I: wherein: R 1 and R 2 are each independently OH, acetyl, or a cyclic ketal ring or cyclic carbonate ester formed by the C3 and C4 of the fucosyl unit, R 1 , and R 2 ; R 3 is a carboxyl group, R 4 -NR 5 -C(O)—, or an alkoxy group having the structure R 4 —O—, wherein R 4 is a saccharide unit or a linear chain having the structure R 7 (CH 2 ) 0-20 -, and wherein R 7 is OH, COOH, COOMe, COOEt, COOiPr, COOtBu, COOBn, a monophosphoryl lipid A (MPL), or a dipalmitoyl-S-glyceryl cysteine (PamCys) unit, wherein R 5 is a linear chain having the structure R 8 (CH 2 ) 0-20 —, and wherein R 8 is H, OH, COOH, COOMe, COOEt, COOiPr, COOtBu, COOBn, a saccharide unit, a monophosphoryl lipid A (MPL), or a dipalmitoyl-S-glyceryl cysteine (PamCys) unit; and when R 1 and R 2 are both OH, R 3 is not a carboxyl group or COOH(CH 2 ) 0-20 —NH—C(O)—. 3 . The modified saponin of claim 2 , wherein R 1 and R 2 are each OH. 4 . The modified saponin of claim 2 , wherein R 1 and R 2 are each acetyl. 5 . The modified saponin of claim 2 , wherein R 1 and R 2 form an acetonide group protecting the 3-OH and the 4-OH of the fucosyl unit. 6 . The modified saponin of claim 2 , wherein R 1 and R 2 form a carbonate ester group protecting the 3-OH and the 4-OH of the fucosyl unit. 7 . The modified saponin of claim 2 , wherein R 3 is a carboxyl group. 8 . The modified saponin of claim 2 , wherein R 4 is a long-chain fatty acid having the structure HOOC—(CH 2 ) 6-20 —. 9 . The modified saponin of claim 2 , wherein R 4 is a long-chain fatty acid having the structure HOOC—(CH 2 ) 11 . 10 . The modified saponin of claim 2 , wherein R 3 is an alkoxy group having the structure R 7 —(CH 2 ) 6-20 —O—. 11 . The modified saponin of claim 2 , wherein R 4 is a long-chain alcohol having the structure HO—(CH 2 ) 6-20 —. 12 . The modified saponin of claim 2 , wherein R 4 is R 7 —(CH 2 ) 6-20 —. 13 . The modified saponin of claim 2 , wherein the saccharide unit of R 4 is a monosaccharide, a disaccharide, or trisaccharide. 14 . The modified saponin of claim 2 , wherein R 4 is a MPL unit. 15 . The modified saponin of claim 2 , wherein R 4 is a Pam2Cys unit or Pam3Cys unit. 16 . A modified saponin having any of the formulas B-D:
Saponins; Quil A; QS21; ISCOMS · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Expansion of ring D by one atom, e.g. D homo steroids · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Carbocyclic rings · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.